Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MelSort: Adoptive T Cell Transfer in Metastatic Melanoma
NCT02424916Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- May 2015
- Primary completion
- May 2019
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Melan-A-specific CD8+ T cells + MELOE-1-specific CD8+ T cells in melanoma, sponsored by CHU de Nantes. Started May 2015; status: completed.
02
Drugs
Melan-A-specific CD8+ T cells + MELOE-1-specific CD8+ T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02424916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02424916.